Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality.

Li C, Zhu B, Son YM, Wang Z, Jiang L, Xiang M, Ye Z, Beckermann KE, Wu Y, Jenkins JW, Siska PJ, Vincent BG, Prakash YS, Peikert T, Edelson BT, Taneja R, Kaplan MH, Rathmell JC, Dong H, Hitosugi T, Sun J.

Immunity. 2019 Sep 17;51(3):491-507.e7. doi: 10.1016/j.immuni.2019.08.013.

PMID:
31533057
2.

Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.

Dudzinski SO, Cameron BD, Wang J, Rathmell JC, Giorgio TD, Kirschner AN.

J Immunother Cancer. 2019 Aug 14;7(1):218. doi: 10.1186/s40425-019-0704-z.

3.

Mitochondrial Homeostasis in AML and Gasping for Response in Resistance to BCL2 Blockade.

Savona MR, Rathmell JC.

Cancer Discov. 2019 Jul;9(7):831-833. doi: 10.1158/2159-8290.CD-19-0510.

PMID:
31262744
4.

Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells.

Babaer D, Amara S, McAdory BS, Johnson O, Myles EL, Zent R, Rathmell JC, Tiriveedhi V.

Cancers (Basel). 2019 May 14;11(5). pii: E672. doi: 10.3390/cancers11050672.

5.

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.

van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW.

Blood. 2019 Jul 4;134(1):44-58. doi: 10.1182/blood.2018885863. Epub 2019 May 10.

PMID:
31076448
6.

Antigen receptor control of methionine metabolism in T cells.

Sinclair LV, Howden AJ, Brenes A, Spinelli L, Hukelmann JL, Macintyre AN, Liu X, Thomson S, Taylor PM, Rathmell JC, Locasale JW, Lamond AI, Cantrell DA.

Elife. 2019 Mar 27;8. pii: e44210. doi: 10.7554/eLife.44210.

7.

Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells.

Gemta LF, Siska PJ, Nelson ME, Gao X, Liu X, Locasale JW, Yagita H, Slingluff CL Jr, Hoehn KL, Rathmell JC, Bullock TNJ.

Sci Immunol. 2019 Jan 25;4(31). pii: eaap9520. doi: 10.1126/sciimmunol.aap9520.

8.

Myeloid Slc2a1-Deficient Murine Model Revealed Macrophage Activation and Metabolic Phenotype Are Fueled by GLUT1.

Freemerman AJ, Zhao L, Pingili AK, Teng B, Cozzo AJ, Fuller AM, Johnson AR, Milner JJ, Lim MF, Galanko JA, Beck MA, Bear JE, Rotty JD, Bezavada L, Smallwood HS, Puchowicz MA, Liu J, Locasale JW, Lee DP, Bennett BJ, Abel ED, Rathmell JC, Makowski L.

J Immunol. 2019 Feb 15;202(4):1265-1286. doi: 10.4049/jimmunol.1800002. Epub 2019 Jan 18.

9.

Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release.

Morioka S, Perry JSA, Raymond MH, Medina CB, Zhu Y, Zhao L, Serbulea V, Onengut-Gumuscu S, Leitinger N, Kucenas S, Rathmell JC, Makowski L, Ravichandran KS.

Nature. 2018 Nov;563(7733):714-718. doi: 10.1038/s41586-018-0735-5. Epub 2018 Nov 21.

10.

Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.

Greenplate AR, McClanahan DD, Oberholtzer BK, Doxie DB, Roe CE, Diggins KE, Leelatian N, Rasmussen ML, Kelley MC, Gama V, Siska PJ, Rathmell JC, Ferrell PB, Johnson DB, Irish JM.

Cancer Immunol Res. 2019 Jan;7(1):86-99. doi: 10.1158/2326-6066.CIR-17-0692. Epub 2018 Nov 9.

PMID:
30413431
11.

Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism.

Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, Newcomb DC, Wells AD, Restifo NP, Rathmell WK, Locasale JW, Davila ML, Blazar BR, Rathmell JC.

Cell. 2018 Dec 13;175(7):1780-1795.e19. doi: 10.1016/j.cell.2018.10.001. Epub 2018 Nov 1.

PMID:
30392958
12.

Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions.

Rathmell WK, Rathmell JC, Linehan WM.

J Clin Oncol. 2018 Oct 29:JCO2018792309. doi: 10.1200/JCO.2018.79.2309. [Epub ahead of print]

PMID:
30372395
13.

Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Chatterjee S, Chakraborty P, Daenthanasanmak A, Iamsawat S, Andrejeva G, Luevano LA, Wolf M, Baliga U, Krieg C, Beeson CC, Mehrotra M, Hill EG, Rathmell JC, Yu XZ, Kraft AS, Mehrotra S.

Clin Cancer Res. 2019 Feb 1;25(3):1036-1049. doi: 10.1158/1078-0432.CCR-18-0706. Epub 2018 Oct 16.

PMID:
30327305
14.

Cutting Edge: TGF-β and Phosphatidylinositol 3-Kinase Signals Modulate Distinct Metabolism of Regulatory T Cell Subsets.

Priyadharshini B, Loschi M, Newton RH, Zhang JW, Finn KK, Gerriets VA, Huynh A, Rathmell JC, Blazar BR, Turka LA.

J Immunol. 2018 Oct 15;201(8):2215-2219. doi: 10.4049/jimmunol.1800311. Epub 2018 Sep 12.

15.

Mutant KRAS Exosomes Alter the Metabolic State of Recipient Colonic Epithelial Cells.

Zhang Q, Jeppesen DK, Higginbotham JN, Demory Beckler M, Poulin EJ, Walsh AJ, Skala MC, McKinley ET, Manning HC, Hight MR, Schulte ML, Watt KR, Ayers GD, Wolf MM, Andrejeva G, Rathmell JC, Franklin JL, Coffey RJ.

Cell Mol Gastroenterol Hepatol. 2018 Jan 31;5(4):627-629.e6. doi: 10.1016/j.jcmgh.2018.01.013. eCollection 2018. No abstract available.

16.

xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.

Ji X, Qian J, Rahman SMJ, Siska PJ, Zou Y, Harris BK, Hoeksema MD, Trenary IA, Heidi C, Eisenberg R, Rathmell JC, Young JD, Massion PP.

Oncogene. 2018 Sep;37(36):5007-5019. doi: 10.1038/s41388-018-0307-z. Epub 2018 May 23.

17.

Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis.

Zhang Z, Zi Z, Lee EE, Zhao J, Contreras DC, South AP, Abel ED, Chong BF, Vandergriff T, Hosler GA, Scherer PE, Mettlen M, Rathmell JC, DeBerardinis RJ, Wang RC.

Nat Med. 2018 May;24(5):617-627. doi: 10.1038/s41591-018-0003-0. Epub 2018 Apr 16.

18.

Asymmetric PI3K Activity in Lymphocytes Organized by a PI3K-Mediated Polarity Pathway.

Chen YH, Kratchmarov R, Lin WW, Rothman NJ, Yen B, Adams WC, Nish SA, Rathmell JC, Reiner SL.

Cell Rep. 2018 Jan 23;22(4):860-868. doi: 10.1016/j.celrep.2017.12.087. Epub 2018 Jan 28.

19.

Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.

Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, Kondo J, Coffey RJ, Johnson MO, Rathmell JC, Sharick JT, Skala MC, Smith JA, Berlin J, Washington MK, Nickels ML, Manning HC.

Nat Med. 2018 Feb;24(2):194-202. doi: 10.1038/nm.4464. Epub 2018 Jan 15.

20.

Metabolic Barriers to T Cell Function in Tumors.

Sugiura A, Rathmell JC.

J Immunol. 2018 Jan 15;200(2):400-407. doi: 10.4049/jimmunol.1701041. Review.

21.

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.

Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME, Lee T, Gómez H, Lluch A, Pérez-Fidalgo JA, Wolf MM, Andrejeva G, Rathmell JC, Fesik SW, Arteaga CL.

Cell Metab. 2017 Oct 3;26(4):633-647.e7. doi: 10.1016/j.cmet.2017.09.009.

22.

A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product.

Liberti MV, Dai Z, Wardell SE, Baccile JA, Liu X, Gao X, Baldi R, Mehrmohamadi M, Johnson MO, Madhukar NS, Shestov AA, Chio IIC, Elemento O, Rathmell JC, Schroeder FC, McDonnell DP, Locasale JW.

Cell Metab. 2017 Oct 3;26(4):648-659.e8. doi: 10.1016/j.cmet.2017.08.017. Epub 2017 Sep 14.

23.

Editorial overview: Metabolism of T cells: integrating nutrients, signals, and cell fate.

MacIver NJ, Rathmell JC.

Curr Opin Immunol. 2017 Jun;46:viii-xi. doi: 10.1016/j.coi.2017.06.002. Epub 2017 Jul 3. No abstract available.

24.

Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors.

Andrejeva G, Rathmell JC.

Cell Metab. 2017 Jul 5;26(1):49-70. doi: 10.1016/j.cmet.2017.06.004.

25.

Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma.

Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ, Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, Irish JM, Rathmell WK, Rathmell JC.

JCI Insight. 2017 Jun 15;2(12). pii: 93411. doi: 10.1172/jci.insight.93411. eCollection 2017 Jun 15.

26.

Biochemical Underpinnings of Immune Cell Metabolic Phenotypes.

Olenchock BA, Rathmell JC, Vander Heiden MG.

Immunity. 2017 May 16;46(5):703-713. doi: 10.1016/j.immuni.2017.04.013. Review.

27.

Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.

Siska PJ, Johnpulle RAN, Zhou A, Bordeaux J, Kim JY, Dabbas B, Dakappagari N, Rathmell JC, Rathmell WK, Morgans AK, Balko JM, Johnson DB.

Oncoimmunology. 2017 Mar 20;6(4):e1305535. doi: 10.1080/2162402X.2017.1305535. eCollection 2017.

28.

Dysfunctional T cell metabolism in the tumor microenvironment.

Beckermann KE, Dudzinski SO, Rathmell JC.

Cytokine Growth Factor Rev. 2017 Jun;35:7-14. doi: 10.1016/j.cytogfr.2017.04.003. Epub 2017 Apr 23. Review.

29.

Fine tuning of immunometabolism for the treatment of rheumatic diseases.

Rhoads JP, Major AS, Rathmell JC.

Nat Rev Rheumatol. 2017 May;13(5):313-320. doi: 10.1038/nrrheum.2017.54. Epub 2017 Apr 6. Review.

30.

Metabolic Alterations Contribute to Enhanced Inflammatory Cytokine Production in Irgm1-deficient Macrophages.

Schmidt EA, Fee BE, Henry SC, Nichols AG, Shinohara ML, Rathmell JC, MacIver NJ, Coers J, Ilkayeva OR, Koves TR, Taylor GA.

J Biol Chem. 2017 Mar 17;292(11):4651-4662. doi: 10.1074/jbc.M116.770735. Epub 2017 Feb 1.

31.

Anabolism-Associated Mitochondrial Stasis Driving Lymphocyte Differentiation over Self-Renewal.

Adams WC, Chen YH, Kratchmarov R, Yen B, Nish SA, Lin WW, Rothman NJ, Luchsinger LL, Klein U, Busslinger M, Rathmell JC, Snoeck HW, Reiner SL.

Cell Rep. 2016 Dec 20;17(12):3142-3152. doi: 10.1016/j.celrep.2016.11.065.

32.

Metabolic Signaling Drives IFN-γ.

Siska PJ, Rathmell JC.

Cell Metab. 2016 Nov 8;24(5):651-652. doi: 10.1016/j.cmet.2016.10.018.

33.

Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression.

Gerriets VA, Kishton RJ, Johnson MO, Cohen S, Siska PJ, Nichols AG, Warmoes MO, de Cubas AA, MacIver NJ, Locasale JW, Turka LA, Wells AD, Rathmell JC.

Nat Immunol. 2016 Dec;17(12):1459-1466. doi: 10.1038/ni.3577. Epub 2016 Oct 3.

34.

Nutrients and the microenvironment to feed a T cell army.

Johnson MO, Siska PJ, Contreras DC, Rathmell JC.

Semin Immunol. 2016 Oct;28(5):505-513. doi: 10.1016/j.smim.2016.09.003. Epub 2016 Oct 3. Review.

35.

mTORC1 and mTORC2 Kinase Signaling and Glucose Metabolism Drive Follicular Helper T Cell Differentiation.

Zeng H, Cohen S, Guy C, Shrestha S, Neale G, Brown SA, Cloer C, Kishton RJ, Gao X, Youngblood B, Do M, Li MO, Locasale JW, Rathmell JC, Chi H.

Immunity. 2016 Sep 20;45(3):540-554. doi: 10.1016/j.immuni.2016.08.017. Epub 2016 Sep 13.

36.

Fluorescence-based measurement of cystine uptake through xCT shows requirement for ROS detoxification in activated lymphocytes.

Siska PJ, Kim B, Ji X, Hoeksema MD, Massion PP, Beckermann KE, Wu J, Chi JT, Hong J, Rathmell JC.

J Immunol Methods. 2016 Nov;438:51-58. doi: 10.1016/j.jim.2016.08.013. Epub 2016 Sep 2.

37.

Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.

Siska PJ, van der Windt GJ, Kishton RJ, Cohen S, Eisner W, MacIver NJ, Kater AP, Weinberg JB, Rathmell JC.

J Immunol. 2016 Sep 15;197(6):2532-40. doi: 10.4049/jimmunol.1502464. Epub 2016 Aug 10.

38.

AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival.

Kishton RJ, Barnes CE, Nichols AG, Cohen S, Gerriets VA, Siska PJ, Macintyre AN, Goraksha-Hicks P, de Cubas AA, Liu T, Warmoes MO, Abel ED, Yeoh AE, Gershon TR, Rathmell WK, Richards KL, Locasale JW, Rathmell JC.

Cell Metab. 2016 Apr 12;23(4):649-62. doi: 10.1016/j.cmet.2016.03.008.

39.

ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer.

Park S, Chang CY, Safi R, Liu X, Baldi R, Jasper JS, Anderson GR, Liu T, Rathmell JC, Dewhirst MW, Wood KC, Locasale JW, McDonnell DP.

Cell Rep. 2016 Apr 12;15(2):323-35. doi: 10.1016/j.celrep.2016.03.026. Epub 2016 Mar 31.

40.

Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells.

Hosios AM, Hecht VC, Danai LV, Johnson MO, Rathmell JC, Steinhauser ML, Manalis SR, Vander Heiden MG.

Dev Cell. 2016 Mar 7;36(5):540-9. doi: 10.1016/j.devcel.2016.02.012.

41.

Metabolic stress is a barrier to Epstein-Barr virus-mediated B-cell immortalization.

McFadden K, Hafez AY, Kishton R, Messinger JE, Nikitin PA, Rathmell JC, Luftig MA.

Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):E782-90. doi: 10.1073/pnas.1517141113. Epub 2016 Jan 22.

42.

AIF Is "Always In Fashion" for T Cells.

Johnson MO, Rathmell JC.

Immunity. 2016 Jan 19;44(1):11-13. doi: 10.1016/j.immuni.2015.12.015.

43.

IgG-Immune Complexes Promote B Cell Memory by Inducing BAFF.

Kang S, Keener AB, Jones SZ, Benschop RJ, Caro-Maldonado A, Rathmell JC, Clarke SH, Matsushima GK, Whitmire JK, Vilen BJ.

J Immunol. 2016 Jan 1;196(1):196-206. doi: 10.4049/jimmunol.1402527. Epub 2015 Nov 30.

44.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

45.

Dysregulated metabolism contributes to oncogenesis.

Hirschey MD, DeBerardinis RJ, Diehl AME, Drew JE, Frezza C, Green MF, Jones LW, Ko YH, Le A, Lea MA, Locasale JW, Longo VD, Lyssiotis CA, McDonnell E, Mehrmohamadi M, Michelotti G, Muralidhar V, Murphy MP, Pedersen PL, Poore B, Raffaghello L, Rathmell JC, Sivanand S, Vander Heiden MG, Wellen KE; Target Validation Team.

Semin Cancer Biol. 2015 Dec;35 Suppl:S129-S150. doi: 10.1016/j.semcancer.2015.10.002. Epub 2015 Oct 8. Review.

46.

MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.

Altman BJ, Hsieh AL, Sengupta A, Krishnanaiah SY, Stine ZE, Walton ZE, Gouw AM, Venkataraman A, Li B, Goraksha-Hicks P, Diskin SJ, Bellovin DI, Simon MC, Rathmell JC, Lazar MA, Maris JM, Felsher DW, Hogenesch JB, Weljie AM, Dang CV.

Cell Metab. 2015 Dec 1;22(6):1009-19. doi: 10.1016/j.cmet.2015.09.003. Epub 2015 Sep 17.

47.

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.

Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, Tsui YC, Cui G, Micevic G, Perales JC, Kleinstein SH, Abel ED, Insogna KL, Feske S, Locasale JW, Bosenberg MW, Rathmell JC, Kaech SM.

Cell. 2015 Sep 10;162(6):1217-28. doi: 10.1016/j.cell.2015.08.012. Epub 2015 Aug 27.

48.

PKCs Sweeten Cell Metabolism by Phosphorylation of Glut1.

Siska PJ, Rathmell JC.

Mol Cell. 2015 Jun 4;58(5):711-2. doi: 10.1016/j.molcel.2015.05.025.

49.

HIF-1 Alpha Regulates the Response of Primary Sarcomas to Radiation Therapy through a Cell Autonomous Mechanism.

Zhang M, Qiu Q, Li Z, Sachdeva M, Min H, Cardona DM, DeLaney TF, Han T, Ma Y, Luo L, Ilkayeva OR, Lui K, Nichols AG, Newgard CB, Kastan MB, Rathmell JC, Dewhirst MW, Kirsch DG.

Radiat Res. 2015 Jun;183(6):594-609. Epub 2015 May 14.

50.

Novel therapeutic targets of tumor metabolism.

Kishton RJ, Rathmell JC.

Cancer J. 2015 Mar-Apr;21(2):62-9. doi: 10.1097/PPO.0000000000000099. Review.

Supplemental Content

Loading ...
Support Center